The market for NF-κB inhibitors is expected to experience significant growth due to the rising cases of cancer, autoimmune disorders, and inflammatory conditions associated with NF-κB activation. This market expansion is fueled by the anticipated introduction of new NF-κB inhibitors like BioVie's bezisterim (NE3107) and Entero Therapeutics' products. These developments underscore the market's potential, with the increasing demand for treatments targeting NF-κB signaling pathways in diseases.